# Leveraging NAMs to understand disease triggers, discover early biomarkers and develop new classes of therapeutic strategies for Type 1 Diabetes (U01 Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/rfa-dk-28-113-leveraging-nams-to-understand-disease-triggers-discover/  
Official notice: https://www.grants.gov/search-results-detail/364219

> National Institutes of Health plans to offer grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expects to make about 12 awards worth $12.0 million in total. It is a forecast: the notice is expected around December 1, 2026, with applications due around February 10, 2027.

| Field | Value |
|---|---|
| Opportunity number | RFA-DK-28-113 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | expected February 10, 2027 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 12 |
| Total funding | $12.0 million |
| Cost sharing | not required |
| Assistance Listings | 93.855, 93.KRP |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

## What the grant funds

This NOFO will support research using human-relevant New Approach Methodologies (NAMs) to advance understanding of the earliest events that initiate and drive Type 1 Diabetes (T1D). Projects will use human cells and tissues and innovative experimental and computational approaches–including organoids, microphysiological systems, and other advanced human-relevant models–to investigate cellular and molecular mechanisms involved in T1D initiation and early disease progression. The research is expected to identify and validate early biomarkers and therapeutic targets and advance new strategies to prevent or interrupt disease progression before substantial pancreatic beta cell loss occurs. Funded projects will become part of the Human Islet Research Network (HIRN), providing a collaborative environment that brings together complementary expertise, technologies, human biological resources, and datasets. Awardees will be expected to participate in collaborative activities, share tools and data, coordinate the use of scarce human pancreatic tissues, and promote harmonization and interoperability of approaches and datasets where appropriate. Through this coordinated research effort, the initiative seeks to overcome barriers that have limited progress by individual laboratories and accelerate the translation of discoveries about early human T1D into biomarkers, therapeutic targets, and ultimately preventive or treatment strategies.

## Questions people ask

### Is RFA-DK-28-113 still open?

Not yet. It is a forecast: expected deadline February 10, 2027.

### Who can apply for Leveraging NAMs to understand disease triggers, discover early biomarkers and develop new classes of therapeutic strategies for Type 1 Diabetes (U01 Clinical Trial Not Allowed)?

National Institutes of Health accepts applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Leveraging NAMs to understand disease triggers, discover early biomarkers and develop new classes of therapeutic strategies for Type 1 Diabetes (U01 Clinical Trial Not Allowed)?

Expected deadline February 10, 2027. Confirm the date and time in the official notice on Grants.gov.

### How much funding is available?

About $12.0 million in total across about 12 awards.

### Who has won Allergy and Infectious Diseases Research grants before?

The largest recipients over five fiscal years were Fred Hutchinson Cancer Center, Duke University, University of California, Los Angeles. The program made 13,282 awards worth $22 billion in that time.